Of particular note, a PD-L1 inhibitor, durvalumab, administered after chemoradiotherapy (CRT) for inoperable stage III NSCLC successfully showed survival benefits compared to CRT alone in a phase 3 randomized controlled trial (RCT) [11,12]. Here, CD274 is linked to non-small cell lung carcinoma.